UniPharma Co., Ltd. (TPEX:6621)
Taiwan
· Delayed Price · Currency is TWD 12.45
0.00 (0.00%)
Mar 10, 2026, 1:55 PM CST
UniPharma Revenue
UniPharma had revenue of 44.32M TWD in the half year ending June 30, 2025, a decrease of -12.51%. This brings the company's revenue in the last twelve months to 90.79M, down -8.81% year-over-year. In the year 2024, UniPharma had annual revenue of 93.46M, down -9.46%.
Revenue (ttm)
90.79M
Revenue Growth
-8.81%
P/S Ratio
4.87
Revenue / Employee
2.93M
Employees
31
Market Cap
441.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 93.46M | -9.77M | -9.46% |
| Dec 31, 2023 | 103.22M | -24.89M | -19.43% |
| Dec 31, 2022 | 128.11M | 22.72M | 21.56% |
| Dec 31, 2021 | 105.39M | -33.25M | -23.98% |
| Dec 31, 2020 | 138.64M | -15.64M | -10.14% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| General Biologicals | 251.38M |
| Bioray Biotech | 230.06M |
| Prince Pharmaceutical | 798.27M |
| Mediera | 229.85M |
| Original BioMedicals | 381.00K |
| Anxo Pharmaceutical | 883.22M |
| Excelsior Biopharma | 898.26M |
| DV Biomed | 712.61M |